Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic profiling of melanomas treated with BRAF inhibitor

ABSTRACT: Transcriptomic profiling of melanomas treated with BRAF inhibitor

PROVIDER: PRJNA678300 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13055377_1.fastq.gz	Fastqsanger.gz
	SRR13055377_2.fastq.gz	Fastqsanger.gz
	SRR13055378_1.fastq.gz	Fastqsanger.gz
	SRR13055378_2.fastq.gz	Fastqsanger.gz
	SRR13055379_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 28

Similar Datasets

Anti-BRAF mutation drug resistance enhances EGFR expression in melanomas [methylation profiling]

2014-12-17 | GSE45647 | GEO

Anti-BRAF mutation drug resistance enhances EGFR expression in melanomas [expression profiling]

2014-12-17 | GSE45648 | GEO

Transcriptomic profiling of melanomas treated with BRAF inhibitor

Project description:Since tumor early response is a timing sensitive progress, accurate time points for biopsy collection will provide a fundament for the investigation of the correlation between angiogenesis and BRAFi resistance. To this end, we recapitulated the clinical therapeutic process with a mouse model. SMM102, a BRAFi sensitive mouse cell line, was subcutaneously inoculated on both flanks of C57BL/6 mice. Mice were treated with BRAFi and sacrificed at different time point.

2020-11-14 | GSE161430 | GEO

Anti-BRAF mutation drug resistance enhances EGFR expression in melanomas [expression profiling]

Project description:We treated melanoma cells with BRAF mutation with BRAF inhibitor and screened for BRAF inhibitor resistant cells. We extracted total mRNA from parental cells and resistant cell lines. We compared their expression by carried out Affymetrix Huex 1.0 ST expression array. Two paired parental/derived cell lines were screened as per the summary above. BRAF inhibitory resistant cells had gene expression compared to the parental cell lines.

2014-12-17 | E-GEOD-45648 | biostudies-arrayexpress

Anti-BRAF mutation drug resistance enhances EGFR expression in melanomas [methylation profiling]

Project description:We treated melanoma cells with BRAF mutation with BRAF inhibitor and screened for BRAF inhibitor resistant cells. We extracted DNA from parental cells and resistant cell lines. We compared the DNA methylation via Illumina 450K Methylation Array Bisulphite converted DNA from the 4 specimens was hybridised to the Illumina Infinium 450k Human Methylation Beadchip

2014-12-17 | E-GEOD-45647 | biostudies-arrayexpress

Beta-catenin Controls Metastasis in Braf-activated Pten-inactivated Melanomas

Project description:Malignant melanoma is characterized by frequent metastasis, however specific changes that regulate this process have not been clearly delineated. Although it is well known that Wnt signaling is frequently dysregulated in melanoma, the functional implications of this observation are unclear. By modulating beta-catenin levels in a mouse model of melanoma that is based on melanocyte-specific Pten loss and BrafV600E mutation, we demonstrate that beta-catenin is a central mediator of melanoma metastasis to lymph node and lung. In addition to altering metastasis, beta-catenin levels control tumor differentiation and regulate both MAPK/Erk and PI3K/Akt signaling. Highly metastatic tumors with beta-catenin stabilization are very similar to a subset of human melanomas; together these findings establish Wnt signaling as a metastasis regulator in melanoma. MoGene-1_0-st-v1: Four samples total. Two biological replicates of uncultured Pten/Braf murine melanomas and two biological replicates of uncultured Pten/Braf/Bcat-STA murine melanomas. MoEx-1_0-st-v1: Two samples total. Dissociated tumor and FACS-enriched Pten/Braf and Pten/Braf/Bcat-STA murine melanoma.

2011-10-12 | E-GEOD-32907 | biostudies-arrayexpress

protein levels in BRAF inhibitor resistance melanoma cells treated with PF3758309

Project description:11 BRAF inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)

2017-07-31 | GSE96753 | GEO

Identification of distinct molecular signatures in BRAF V600E and BRAF wt cutaneous melanomas

Project description:The purpose of this study was to investigate the presence of a gene expression signature in BRAF V600E melanomas compared to wild type ones, all derived from sun-exposed sites. Microdissected tissues from excisional biopsies of 18 cutaneous melanomas were analyzed to detect the presence of BRAF and NRAS mutations and to profile whole genome expression by means of oligonucleotide microarrays. Class comparison methods were used to select differentially expressed genes between wild type and mutated lesions. Real Time RT-PCR and immunohistochemistry were applied to validate differences at the mRNA and protein levels on an independent cohort of samples. BRAF mutations were evidenced in 67% of melanomas. All of them consisted of the oncogenic change V600E (and the mutation event was independent of Clark's level). Data indicate that in V600E melanomas there is an over-expression of cancer stem cell markers and an upregulation of important oncogenes, like KRAS. This, together with the downregulation of genes involved in oxidative UV stress response and immuno system defense, confers an advantage to V600E melanomas compared to wt lesions. Moreover, the downregulation of topoisomerase I and CDKN2A results in an increased replicative potential associated with a decrease in senescence markers and a diminished DNA damage response. As far as the wild-type lesions, we interestingly pointed out the overexpression of PML, PIK3CA and the downregulation of two tumour suppressor genes (BRCA1 and TP73) relevant to DNA repair.

2024-12-31 | GSE22838 | GEO

protein levels in BRAF/MEK inhibitor resistance melanoma cells treated with PF3758309 [CR]

Project description:3 BRAF/MEK inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)

2017-07-31 | GSE96902 | GEO

Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition

Project description:Approximately 50% of melanomas harbor an activating BRAFV600E mutation. Standard of care involves a combination of inhibitors targeting mutant BRAF and MEK1/2, the substrate for BRAF in the MAPK pathway. PTEN loss of function mutations occur in 40% of BRAFV600E melanomas, resulting in increased PI3K/AKT activity that enhances resistance to BRAF/MEK combination inhibitor therapy. To compare the response of PTEN null to PTEN wild type cells in an isogenic background, CRISPR was used to knock out PTEN a melanoma cell line that harbors a BRAFV600E mutation. RNA sequencing and functional kinome analysis revealed the loss of PTEN led to an induction of FOXD3 and an increase in expression of the FOXD3 target gene, ERBB3/HER3. Inhibition of BRAF and MEK1/2 in PTEN null, BRAFV600Ecells dramatically induced expression of ERBB3/HER3 relative to wild type cells. A synergy screen of epigenetic modifiers and kinase inhibitors in combination with BRAFi/MEKi identified the pan ERBB/HER inhibitor, neratinib, as reversing the resistance observed in PTEN null, BRAFV600Ecells. The findings indicate that PTEN null BRAFV600E melanoma exhibits increased reliance on ERBB/HER signaling when treated with clinically approved BRAFi/MEKi combinations. Future studies are warranted to test neratinib reversal of resistance in patient melanomas expressing ERBB3/HER3 in combination with its dimerization partner ERBB2/HER2.

2024-04-23 | GSE255541 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data